More delays in GTG-Applera case
Monday, 05 December, 2005
Two deadlines have come and gone, and a third expires today for Melbourne gene-testing company Genetic Technologies (ASX:GTG; NASDAQ:GENE) and US firm Applera, who were due to announce a resolution of their licensing dispute in California today.
GTG has been pursuing its US rival in the US District Court of Northern California for a licensing fee and royalties for its patented technologies, which uses 'junk DNA' markers to identify haplotypes associated with disease.
The case was originally due to be resolved by a court-sanctioned agreement on November 9, but the companies postponed their execution of a binding settlement, and licence and supply issues until November 25. When November 25 passed, Judge Joseph Spero approved a requested delay until December 5.
After a telephone conference with both parties, Judge Spero has now granted a further extension to Wednesday, December 8, and ordered lawyers and company representatives to attend a further settlement conference in San Francisco.
GTG said the delay was "a positive development in the progress of this matter
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
